The microRNA-218~Survivin axis regulates migration, invasion, and lymph node metastasis in cervical cancer

Oncotarget

Volumn 6, Issue 2, 2015, Pages 1090-1100

  Kogo, Ryunosuke ^a   How, Christine ^a   Chaudary, Naz ^a   Bruce, Jeff ^a   Shi, Wei ^a   Hill, Richard P ^a,b   Zahedi, Payam ^a   Yip, Kenneth W ^a   Liu, Fei Fei ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cervical cancer; Invasion; Migration; miR 218; Survivin

Indexed keywords

MICRORNA; MICRORNA 218; SEPANTRONIUM BROMIDE; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; MIRN218 MICRORNA, HUMAN; NAPHTHOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CLONOGENESIS; COMPUTER MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; 3' UNTRANSLATED REGION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION; UTERINE CERVICAL NEOPLASMS; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MICE, SCID; MICRORNAS; MIDDLE AGED; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921825261     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2836     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001; 358: 781-786.
3. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, 3rd, Walker JL and Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340: 1154-1161.
4. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340: 1137-1143.
5. American Cancer Society. Cervical Cancer. Atlanta, Ga: American Cancer Society. 2013.
6. Waggoner SE. Cervical cancer. Lancet. 2003; 361: 2217-2225.
7. Sethi N and Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Cancer. 2011; 11: 735-748.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
9. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6: 857-866.
10. Hu X, Schwarz JK, Lewis JS, Jr., Huettner PC, Rader JS, Deasy JO, Grigsby PW and Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010; 70: 1441-1448.
11. Lui WO, Pourmand N, Patterson BK and Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007; 67: 6031-6043.
12. Alajez NM, Lenarduzzi M, Ito E, Hui AB, Shi W, Bruce J, Yue S, Huang SH, Xu W, Waldron J, O'Sullivan B and Liu FF. MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res. 2011; 71: 2381-2391.
13. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE, Passmore LH, Bowman RV and Fong KM. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One. 2010; 5: e12560.
14. Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE and Chen Y. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013; 144: 1086-1097 e1089.
15. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y and Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010; 6: e1000879.
16. Yu J, Wang Y, Dong R, Huang X, Ding S and Qiu H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 2012; 138: 671-674.
17. How C, Hui AB, Alajez NM, Shi W, Boutros PC, Clarke BA, Yan R, Pintilie M, Fyles A, Hedley DW, Hill RP, Milosevic M and Liu FF. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS One. 2013; 8: e67846.
18. Tatarano S, Chiyomaru T, Kawakami K, Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama K, Seki N and Nakagawa M. miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. Int J Oncol. 2011; 39: 13-21.
19. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA. 2008; 14: 1012-1017.
20. Wang X and El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2008; 24: 325-332.
21. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008; 8: 61-70.
22. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 332: 225-228.
23. Rauch A, Hennig D, Schafer C, Wirth M, Marx C, Heinzel T, Schneider G and Kramer OH. Survivin and YM155: how faithful is the liaison? Biochim Biophys Acta. 2014; 1845: 202-220.
24. Chaudary N, Hedley DW and Hill RP. Orthotopic xenograft model of cervical cancer for studying microenvironmental effects on metastasis formation and response to drug treatment. Curr Protoc Pharmacol. 2011; Chapter 14: Unit 14 19.
25. Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, Yu C, Wu Z and Li J. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010; 402: 135-140.
26. Kinoshita T, Hanazawa T, Nohata N, Kikkawa N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto Y and Seki N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget. 2012; 3: 1386-1400.
27. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M and Enokida H. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol. 2013; 190: 1059-1068.
28. Yamamoto N, Kinoshita T, Nohata N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. Int J Oncol. 2013; 42: 1523-1532.
29. van den Tillaart SA, Corver WE, Ruano Neto D, ter Haar NT, Goeman JJ, Trimbos JB, Fleuren GJ and Oosting J. Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer. PLoS One. 2013; 8: e67414.
30. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011; 71: 5765-5778.
31. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T and Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010; 17: 53-64.
32. Yamauchi T, Nakamura N, Hiramoto M, Yuri M, Yokota H, Naitou M, Takeuchi M, Yamanaka K, Kita A, Nakahara T, Kinoyama I, Matsuhisa A, Kaneko N, Koutoku H, Sasamata M, Kobori M, et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem Biophys Res Commun. 2012; 425: 711-716.
33. Thorvaldsdottir H, Robinson JT and Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178-192.